Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of EVGN opened at $2.46 on Friday. The stock has a 50-day moving average of $2.93 and a 200-day moving average of $5.11. Evogene has a one year low of $2.14 and a one year high of $10.40.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The firm had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets boosted its holdings in Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.